Elypta

Elypta

Private
SolnaHealthcare & Life Scienceshttps://elypta.com

Last Round

Series A

Jun 20, 2022

Total Funding Raised

$23.69M

Momentum Score

25 /100

Company Overview

Elypta is a biotechnology company that is developing a metabolism-based liquid biopsy platform designed for the early detection and monitoring of cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Medical Devices, Medical AI, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales, Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

liquid biopsyearly cancer detectionmulti-cancer early detectionMCEDcancer diagnosticsGAGomemetabolic biomarkerscancer recurrence monitoringmolecular diagnosticsMDxmass spectrometryglycosaminoglycan biomarkerspan-cancer testkidney cancer monitoringresearch use onlyRUOdiagnostic kitUHPLC-MS

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Elypta Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Elypta Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series AJun 20, 2022
GrantFeb 4, 2019

Key People

Founding team and executive leadership

Karl Bergman

CEO

Executive Team

Johan Vikström

Chief Financial Officer

Executive Team

Elypta Investors

Notable investors and investment history

InvestorRounds
Nina CapitalSeries A
Bonnier CapitalSeries A
HillclimberSeries A
Navigare VenturesSeries A
IndustrifondenSeries A
Chalmers VenturesSeries A
Norrsken VCSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 1, 2026

    Monthly visitors grew 96% MoM.

  • Apr 7, 2025

    Dr. Hilja Ibert appointed to the Board of Directors.

Elypta Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Elypta Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Elypta's valuation, stock price, and market status.

Firmographic Details

HeadquartersSolna
Employee Range30
Year Founded2017
Last FundingJun 20, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.